4.7 Article

Genotype patterns at PICALM, CR1, BIN1, CLU, and APOE genes are associated with episodic memory

期刊

NEUROLOGY
卷 78, 期 19, 页码 1464-1471

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3182553c48

关键词

-

资金

  1. NIH [HHSN268200782096C]
  2. NIA [U24AG26396, U24AG021886, R01AG17917, P50AG8702, P30AG10161, P30AG013846, P30AG028377, P30AG010133, P50AG05134, P50AG016574]
  3. NSFC from the Chinese Government [30730057]
  4. Alzheimer Disease Genetic Consortium
  5. Athena Diagnostics, Inc.
  6. AstraZeneca
  7. Genetech
  8. Pfizer
  9. Danone Research
  10. Elan Pharma
  11. Eli Lilly
  12. Novartis
  13. OctaPharma
  14. sanofi-aventis
  15. Sonexa Therapeutics
  16. Eisai
  17. Medivation
  18. Janssen
  19. Allon
  20. Forest
  21. Cephalon Inc.
  22. Allon Pharmaceuticals
  23. Mangurian Foundation
  24. Alzheimer Association
  25. Behavioral Neurology of Dementia
  26. Rush University Medical Center
  27. Natural Science Foundation of China
  28. N I A [P50AG05138, P30AG013854, P30AG08017, P50AG016582, P50AG016570, P30AG028383, P30AG010124, P50AG005133, R01AG027224, P50AG05142, P30AG012300, P50AG05136, P50AG05681]

向作者/读者索取更多资源

Objective: Several genome-wide association studies (GWAS) have associated variants in late-onset Alzheimer disease (LOAD) susceptibility genes; however, these single nucleotide polymorphisms (SNPs) have very modest effects, suggesting that single SNP approaches may be inadequate to identify genetic risks. An alternative approach is the use of multilocus genotype patterns (MLGPs) that combine SNPs at different susceptibility genes. Methods: Using data from 1,365 subjects in the National Institute on Aging Late-Onset Alzheimer's Disease Family Study, we conducted a family-based association study in which we tabulated MLGPs for SNPs at CR1, BIN1, CLU, PICALM, and APOE. We used generalized estimating equations to model episodic memory as the dependent endophenotype of LOAD and the MLGPs as predictors while adjusting for sex, age, and education. Results: Several genotype patterns influenced episodic memory performance. A pattern that included PICALM and CLU was the strongest genotypic profile for lower memory performance (beta = -0.32, SE = 0.19, p = 0.021). The effect was stronger after addition of APOE (p = 0.016). Two additional patterns involving PICALM, CR1, and APOE and another pattern involving PICALM, BIN1, and APOE were also associated with significantly poorer memory performance (beta = -0.44, SE = 0.09, p = 0.009 and beta = -0.29, SE = 0.07, p = 0.012) even after exclusion of patients with LOAD. We also identified genotype pattern involving variants in PICALM, CLU, and APOE as a predictor of better memory performance (beta = 0.26, SE = 0.10, p = 0.010). Conclusions: MLGPs provide an alternative analytical approach to predict an individual's genetic risk for episodic memory performance, a surrogate indicator of LOAD. Identifying genotypic patterns contributing to the decline of an individual's cognitive performance may be a critical step along the road to preclinical detection of Alzheimer disease. Neurology (R) 2012;78:1464-1471

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据